Evaluating of Role of Myeloperoxidase in Prediction of Outcomes of Cardiac Surgery Procedures.

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03786965

Acronym

MPO-CSP

Enrollment

2000

Registered

2018-12-26

Start date

2018-12-20

Completion date

2025-12-20

Last updated

2021-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Procedure Complication, Defect Septal, Ischemic Heart Disease, Valve Heart Disease

Keywords

Ischemic Heart Disease, Valve Disease, Septal Defect, Myeloperoxidase, Molecular biology, Gene analysis

Brief summary

The main objection is to investigate molecular biology of myocardial damage during cardiac surgery procedures.

Detailed description

To assess outcomes after cardiac surgery procedures. To investigate serum level of myeloperoxidase, morphology of left atrium appendage, to perform genetic analysis and cell biology.

Interventions

OTHEROn-pump CABG

On-pump CABG

OTHEROff-pump CABG

Off-pump CABG

OTHERPump-assisted CABG

Pump-assisted CABG

OTHERValve Repair Procedure without CABG.

Valve Repair Procedure without CABG (open heart procedure).

OTHERValve Repair Procedure with CABG.

Valve Repair Procedure with CABG (open heart procedure).

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* ischemic heart disease with indications for operation * valve disease with indications for operation * ischemic heart disease combined with valve disease with indications for operation

Exclusion criteria

* patient refusal

Design outcomes

Primary

Measure	Time frame	Description
Death within 30 days after procedure.	within 30 days after procedure.	Death within 30 days after surgical procedure.
Acute myocardial infarction.	within 30 days after procedure.	Acute myocardial infarction (ST-changes with troponin I \> 10 ng/ml).
Stroke.	within 30 days after procedure.	Stroke (MRI changes or corresponding neurologist record).
Arrhythmia	within 30 days after procedure.	Any type of arrhythmia including AV-block.
Renal dysfunction.	within 30 days after procedure.	Renal dysfunction if serum creatinine greater than 25% of upper reference range.
Infection or febrile.	within 30 days after procedure.	Infection or febrile (t\> 37 or CRP elevation or long regeneration of surgical wound).
Respiratory dysfunction.	within 30 days after procedure.	Respiratory dysfunction (pulmonary ventilation longer than 2 days).

Countries

Russia

Contacts

Primary ContactAlexander Nemkov, PhD

nemk_as@mail.ru+7-921-795-00-47

Backup ContactVladimir Komok, PhD

vladimir_komok@mail.ru+7-904-632-19-00

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026